
Sent: Thursday, August 04, 2005 11:39:07 AM

To: Emily Marschke

Subject: Re: Health Technolgy Appraisal - The Clinical effectiveness and cost of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women.

Auto forwarded by a Rule

Emilly,

Thank you for the above document.

On this occasion, the CPHVA are unable to submit any comments on this report.

Many thanks

This e-mail and any files transmitted with it are private and intended solely for the use of the individual or entity to whom they are addressed. If you have received this e-mail in error, please return it to the address it came from telling them it is not for you and then delete it from your system.

